Genmab A/S (0MGB) Stock Statistics & Valuation Metrics

Genmab A/S has a market cap or net worth of kr116.25B. The enterprise value is kr63.39B.

Genmab A/S has 64,206,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genmab A/S’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 14.13%.

The current PE Ratio of Genmab A/S is 13.3. Genmab A/S’s PEG ratio is ―.

In the last 12 months, Genmab A/S had revenue of 21.53B and earned 7.84B in profits. Earnings per share was 122.21.

In the last 12 months, operating cash flow was 5.59B and capital expenditures -363.20M, giving a free cash flow of 5.23B billion.

Genmab A/S pays an annual dividend of ―, resulting in a dividend yield of ―

Genmab A/S upcoming earnings date is Feb 5, 2026, Before Open (Confirmed).

Genmab A/S as a current ratio of 5.25, with Debt / Equity ratio of 2.79%

In the past 12 months, Genmab A/S has paid 1.32B in taxes.

Genmab A/S EV to EBITDA ratio is 9.04, with an EV/FCF ratio of 11.56.

Genmab A/S has kr3.41B in cash and marketable securities with kr143.00M in debt, giving a net cash position of kr3.27B billion.

Gross margin is 94.46%, with operating margin of 31.14%, and net profit margin of 36.44%.

The average price target for Genmab A/S is kr1,959.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy